HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
HARMONY 3: A randomized, double-blind, placebo- and active-controlled trial of 104 weeks assessing the efficacy and safety of albiglutide compared to placebo, sitagliptin and glimepiride in patients with type 2 diabetes taking metformin.